A large meta-analysis has found that hepatocellular carcinoma patients whose CT scans show sarcopenia — the loss of skeletal muscle — fare significantly worse after transarterial chemoembolization, a widely used liver-directed therapy. The analysis, published in BMC Gastroenterology, pooled data from sixteen studies covering 3,359 patients and concluded that CT-defined sarcopenia was significantly associated with both poorer survival and poorer therapeutic response in this population.
The researchers searched PubMed, Web of Science and the CNKI databases up to April 18, 2026, to identify studies examining the prognostic impact of CT-defined sarcopenia in hepatocellular carcinoma patients receiving transarterial chemoembolization, commonly abbreviated as TACE. The procedure delivers chemotherapy and embolizing agents directly into the arteries feeding liver tumors, and it is a standard option for patients whose disease cannot be removed surgically.
The analysis focused on two primary endpoints: overall survival and progression-free survival. Two secondary endpoints — the objective response rate, which measures tumor shrinkage, and the disease control rate, which also accounts for stabilized disease — were examined to capture how well the tumors responded to treatment. Hazard ratios and odds ratios with 95 percent confidence intervals were combined across studies to quantify the impact of sarcopenia on each endpoint.
The results were consistent across both primary outcomes. Patients with CT-defined sarcopenia had a significantly higher risk of death, with a pooled hazard ratio of 1.79 (95 percent confidence interval 1.47 to 2.18, P < 0.001), meaning their hazard of dying during follow-up was roughly 79 percent higher than that of patients without sarcopenia. Progression-free survival showed a similar pattern, with a pooled hazard ratio of 1.65 (95 percent confidence interval 1.42 to 1.92, P < 0.001), indicating that sarcopenic patients were also more likely to experience disease progression earlier.
Importantly, these associations held up when the data were broken down in subgroup analyses stratified by country, sample size, whether TACE was combined with other therapies, the source of the hazard ratio, and the method used to define sarcopenia. The authors reported that these subgroups all manifested similar findings, which strengthens the conclusion that the association is not an artifact of any single study design choice or patient population.
The secondary outcomes pointed in the same direction. Sarcopenia was associated with a decreased objective response rate, with a pooled odds ratio of 0.55 (95 percent confidence interval 0.38 to 0.81, P = 0.002), and a decreased disease control rate, with a pooled odds ratio of 0.50 (95 percent confidence interval 0.37 to 0.67, P < 0.001). In practical terms, patients with muscle loss were roughly half as likely to achieve disease control after TACE compared with those who had preserved muscle mass.
The authors concluded that CT-defined sarcopenia was significantly associated with poorer survival and therapeutic response among hepatocellular carcinoma patients receiving TACE, and that patients with sarcopenia were more likely to experience worse survival and therapeutic response. Because the analysis is observational in nature, pooling existing studies rather than randomizing patients, the findings demonstrate association rather than proven causation, and they cannot establish whether interventions that build or preserve muscle would improve outcomes after TACE.
The study’s background notes that the prognostic impact of CT-defined sarcopenia in this patient group had remained unclear, which the authors cite as the motivation for the analysis. Using CT scans to assess muscle mass is attractive in clinical practice because the imaging is already routinely obtained during the work-up and follow-up of liver cancer patients, avoiding the need for additional testing. The article was published on October 24, 2026, as an open-access research paper in BMC Gastroenterology, authored by Wei Lu, Yanxi Liu, Xinlei Liu, Min Zhu and Wu Wen. The publisher notes that this early-shared version is peer-reviewed and citable, carrying a permanent DOI, and is subject to further edits before the final version of record replaces it.
Subject of Research: The association between CT-defined sarcopenia and survival and therapeutic response in hepatocellular carcinoma patients receiving transarterial chemoembolization.
Article Title: Association of CT-defined sarcopenia with survival and therapeutic response in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis
Article References: Lu, W., Liu, Y., Liu, X., Zhu, M., & Wen, W. (2026). Association of CT-defined sarcopenia with survival and therapeutic response in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-05460-7
Image Credits: AI Generated
DOI: 10.1186/s12876-026-05460-7
Keywords: sarcopenia, hepatocellular carcinoma, transarterial chemoembolization, meta-analysis, overall survival, progression-free survival, objective response rate, disease control rate, CT imaging, liver cancer, prognosis, Association
News Source: Nathaniel Bowman. (October 28, 2026). Muscle Loss on CT Scans Linked to Poorer Survival in Liver Cancer Patients After TACE. Scienmag.
